Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
Sonoma Pharmaceuticals Inc
Other Equity
Sonoma Pharmaceuticals Inc
Other Equity Peer Comparison
Competitive Other Equity Analysis
Latest Figures & CAGR of Competitors
Company | Other Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
|
Other Equity
-$2.8m
|
CAGR 3-Years
13%
|
CAGR 5-Years
9%
|
CAGR 10-Years
1%
|
|
Johnson & Johnson
NYSE:JNJ
|
Other Equity
-$10.8B
|
CAGR 3-Years
11%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-15%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Other Equity
-$1.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
12%
|
CAGR 10-Years
5%
|
|
Pfizer Inc
NYSE:PFE
|
Other Equity
-$8B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
6%
|
CAGR 10-Years
-8%
|
|
Merck & Co Inc
NYSE:MRK
|
Other Equity
-$5.3B
|
CAGR 3-Years
7%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-9%
|
|
Eli Lilly and Co
NYSE:LLY
|
Other Equity
-$4.3B
|
CAGR 3-Years
13%
|
CAGR 5-Years
6%
|
CAGR 10-Years
-7%
|
See Also
What is Sonoma Pharmaceuticals Inc's Other Equity?
Other Equity
-2.8m
USD
Based on the financial report for Dec 31, 2023, Sonoma Pharmaceuticals Inc's Other Equity amounts to -2.8m USD.
What is Sonoma Pharmaceuticals Inc's Other Equity growth rate?
Other Equity CAGR 10Y
1%
Over the last year, the Other Equity growth was 32%. The average annual Other Equity growth rates for Sonoma Pharmaceuticals Inc have been 13% over the past three years , 9% over the past five years , and 1% over the past ten years .